RecruitingNCT06520891
"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"
Sponsor
Fayoum University
Enrollment
90 participants
Start Date
Jun 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
correlate the serum level of statin and SGLT2i when given as polytherapy with HPLC in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)
Eligibility
Min Age: 50 YearsMax Age: 80 Years
Inclusion Criteria2
- we include patients established ischemic heart failure seen by a primary care provider to diagnose ischemic heart disease,
- They assessed the use of statin with SGLT2i.
Exclusion Criteria7
- We exclude patients with
- liver dysfunction.
- renal dysfunction.
- fungal infection.
- coagulation disorder.
- Pts using drugs that interact with SGLT2i.
- patients that will refuse to be enrolled in the Study or refuse to write informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGStatin and SGLT2i
Statin as atrovastatin SGLT2i as dapagliflozin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06520891